Literature DB >> 17051370

Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.

Timothy H Marczylo1, Richard D Verschoyle, Darren N Cooke, Paolo Morazzoni, William P Steward, Andreas J Gescher.   

Abstract

PURPOSE: Curcumin, a major constituent of the spice turmeric, suppresses expression of the enzyme cyclooxygenase 2 (Cox-2) and has cancer chemopreventive properties in rodents. It possesses poor systemic availability. We explored whether formulation with phosphatidylcholine increases the oral bioavailability or affects the metabolite profile of curcumin.
METHODS: Male Wistar rats received 340 mg/kg of either unformulated curcumin or curcumin formulated with phosphatidylcholine (Meriva) by oral gavage. Rats were killed at 15, 30, 60 and 120 min post administration. Plasma, intestinal mucosa and liver were analysed for the presence of curcumin and metabolites using HPLC with UV detection. Identity of curcumin and metabolites was verified by negative ion electrospray liquid chromatography/tandem mass spectrometry.
RESULTS: Curcumin, the accompanying curcuminoids desmethoxycurcumin and bisdesmethoxycurcumin, and the metabolites tetrahydrocurcumin, hexahydrocurcumin, curcumin glucuronide and curcumin sulfate were identified in plasma, intestinal mucosa and liver of rats which had received Meriva. Peak plasma levels and area under the plasma concentration time curve (AUC) values for parent curcumin after administration of Meriva were fivefold higher than the equivalent values seen after unformulated curcumin. Similarly, liver levels of curcumin were higher after administration of Meriva as compared to unformulated curcumin. In contrast, curcumin concentrations in the gastrointestinal mucosa after ingestion of Meriva were somewhat lower than those observed after administration of unformulated curcumin. Similar observations were made for curcumin metabolites as for parent compound.
CONCLUSION: The results suggest that curcumin formulated with phosphatidylcholine furnishes higher systemic levels of parent agent than unformulated curcumin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051370     DOI: 10.1007/s00280-006-0355-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  80 in total

1.  Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice.

Authors:  Liu Zhongfa; Ming Chiu; Jiang Wang; Wei Chen; Winston Yen; Patty Fan-Havard; Lisa D Yee; Kenneth K Chan
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

2.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

3.  Microparticles Containing Curcumin Solid Dispersion: Stability, Bioavailability and Anti-Inflammatory Activity.

Authors:  C C C Teixeira; L M Mendonça; M M Bergamaschi; R H C Queiroz; G E P Souza; L M G Antunes; L A P Freitas
Journal:  AAPS PharmSciTech       Date:  2015-06-04       Impact factor: 3.246

Review 4.  Therapeutic potential of curcumin in digestive diseases.

Authors:  Pietro Dulbecco; Vincenzo Savarino
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

5.  Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice.

Authors:  Agnes Patzkó; Yunhong Bai; Mario A Saporta; István Katona; Xingyao Wu; Domenica Vizzuso; M Laura Feltri; Suola Wang; Lisa M Dillon; John Kamholz; Daniel Kirschner; Fazlul H Sarkar; Lawrence Wrabetz; Michael E Shy
Journal:  Brain       Date:  2012-12       Impact factor: 13.501

6.  A Systematic Review of the Clinical Use of Curcumin for the Treatment of Osteoarthritis.

Authors:  Nafiseh Shokri-Mashhadi; Mohammad Bagherniya; Gholamreza Askari; Thozhukat Sathyapalan; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.

Authors:  Bharat B Aggarwal; Kuzhuvelil B Harikumar
Journal:  Int J Biochem Cell Biol       Date:  2008-07-09       Impact factor: 5.085

8.  Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.

Authors:  Megumi Murakami; Shinobu Ohnuma; Michihiro Fukuda; Eduardo E Chufan; Katsuyoshi Kudoh; Keigo Kanehara; Norihiko Sugisawa; Masaharu Ishida; Takeshi Naitoh; Hiroyuki Shibata; Yoshiharu Iwabuchi; Suresh V Ambudkar; Michiaki Unno
Journal:  Drug Metab Dispos       Date:  2017-09-13       Impact factor: 3.922

9.  Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up.

Authors:  Pia Allegri; Antonio Mastromarino; Piergiorgio Neri
Journal:  Clin Ophthalmol       Date:  2010-10-21

10.  A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin.

Authors:  B Antony; B Merina; V S Iyer; N Judy; K Lennertz; S Joyal
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.